TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
DURHAM, N.C., April 26, 2017 -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against cancer, announced today that Jeff Wolf, Heat’s Founder and CEO, will present at PIONEERS 2017, presented by Joseph Gunnar & Co., on Tuesday, May 2, 2017, at 11:30 a.m. ET. The event will be held at the Mandarin Oriental Hotel in New York City.
Management will be available to meet with investors during the conference. For more information about the conference or to schedule a one-on-one meeting with management, please contact your Joseph Gunnar & Co. representative, email [email protected] or email [email protected].
About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that are designed to activate a patient’s immune system against cancer utilizing an engineered form of gp96, a protein that robustly activates the immune system. Heat’s highly specific T cell-stimulating therapeutic vaccine platform technologies, ImPACT and ComPACT, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients’ immune response. Currently, Heat is conducting a Phase 2 trial with HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC) and a Phase 2 trial with HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC).
Heat’s wholly-owned subsidiary, Zolovax, Inc., is developing therapeutic and preventative vaccines to treat infectious diseases based on Heat’s gp96 vaccine technology, with a current focus on the development of a Zika vaccine in conjunction with the University of Miami.
For more information, please visit www.heatbio.com.
For Investor Inquiries: David Waldman 919-240-7133 [email protected] For Media Inquiries: Deanne Eagle Planet Communications 917-837-5866 [email protected]
